Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a pediatric patient or a patient suffering from a specific condition.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: Method for lyophilisation of a simple of fecal microbiota. The present invention relates to a method for lyophilisation of a sample of fecal microbiota from a donor subject, comprising the following steps: A) mixing of a sample of fecal microbiota from a donor subject with a diluent selected from polyols, disaccharides to pentasaccharides, maltodextrins and mixtures thereof, and B) freezing the mixture obtained in A) at a temperature of less than ?50° C., preferably of between ?70° C. and ?100° C., followed by the lyophilisation thereof.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20- alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: An EIT or differential EIT method in which measurements of voltage differences between electrodes are performed according to a measurement configuration in which at least one of the electrodes injecting a current in the medium being investigated is also used for performing a measurement of the voltage difference. The contact impedances of the different electrodes are measured thanks to a counter-electrode having a contact area with the medium much higher than the contact area of a unit electrode. The measurement of a contact impedance is performed by impedance spectroscopy by comparison with the impedance spectrum of an equivalent circuit. The contact impedances allow voltage drops in the injection electrodes to be calculated the voltage differences between these electrodes and to be corrected. Alternatively, the contact impedances can be used to correct or complete the direct model.

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-C20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: Load manipulating device (1) including a load manipulator (10) including at least two segments (13, 18) articulated with respect to each other, comprising a boom segment (13) that is similarly articulated on a frame (12) and a balance segment (18) which comprises an end intended to receive a load (20) to be manipulated, the load manipulating device (1) including balancing means (41, 23, 24) such that the load manipulator (10) is stable in any position, whether or not bearing the load, and guidance means (50, 60, 70) distinct from the balancing means for constraining the position of the load manipulator (10).

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: An EIT or differential EIT method in which measurements of voltage differences between electrodes are performed according to a measurement configuration in which at least one of the electrodes injecting a current in the medium being investigated is also used for performing a measurement of the voltage difference. The contact impedances of the different electrodes are measured thanks to a counter-electrode having a contact area with the medium much higher than the contact area of a unit electrode. The measurement of a contact impedance is performed by impedance spectroscopy by comparison with the impedance spectrum of an equivalent circuit. The contact impedances allow voltage drops in the injection electrodes to be calculated the voltage differences between these electrodes and to be corrected. Alternatively, the contact impedances can be used to correct or complete the direct model.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: A method for handling of a first robotized mobile machine moving in a congested working environment under the control of a second robotized mobile machine, providing the operator, in real time, with a relevant view of the working scene, even if an object intrudes into the field of view of the camera and thereby obscures the operator's view. This method is based on use of properties of a physics engine of the constraint resolution type. For each object in the scene, the physics engine has a physical representation of said object in the form of a mesh. The engine calculates a wrench on the basis of the respective positions and velocities of two objects. In case of a collision between the manipulator and a fixed object in the scene, the engine determines the wrench to be applied to the manipulator in order to make it avoid the object.